{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/anticoagulation-oral/background-information/licensed-indications/","result":{"pageContext":{"chapter":{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications","depth":2,"htmlHeader":"<!-- begin field 9b757898-2de3-4f0d-ab91-5e186442b3db --><h2>Licensed indications</h2><!-- end field 9b757898-2de3-4f0d-ab91-5e186442b3db -->","summary":"","htmlStringContent":"<!-- begin item 7afe2f9d-cf33-4401-b2f0-525eb3f9e9c6 --><!-- end item 7afe2f9d-cf33-4401-b2f0-525eb3f9e9c6 -->","topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","lastRevised":"January 2021","chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","fullItemName":"Management","slug":"management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"0e9d086b-8217-5383-bb67-f805d67d3bf6","slug":"apixaban","fullItemName":"Apixaban","depth":3,"htmlHeader":"<!-- begin field 171ab8a2-4527-444c-9b65-d811739f2d67 --><h3>What are the licensed indications for apixaban?</h3><!-- end field 171ab8a2-4527-444c-9b65-d811739f2d67 -->","summary":null,"htmlStringContent":"<!-- begin item dc7ce24f-d48a-4686-b156-b6dcd2dcf407 --><!-- begin field d27f7e93-3ab5-4272-ad87-00d4296ca30c --><ul><li><strong>Apixaban is licensed for <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>]</strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>]</strong><strong> </strong><strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>]</strong><strong>:</strong><ul><li>Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more of the following risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2013a</a>]:<ul><li>Previous stroke or transient ischaemic attack.</li><li>Age 75 years or older.</li><li>Hypertension.</li><li>Diabetes mellitus. </li><li>Symptomatic heart failure (New York Heart Association [NYHA] Class 2 or higher).</li></ul></li><li>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2015a</a>].</li><li>Prevention of recurrent DVT and PE in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2015a</a>].</li><li>Prevention of venous thromboembolic events in adults who have undergone elective hip or knee replacement surgery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2012a</a>].</li></ul></li></ul><!-- end field d27f7e93-3ab5-4272-ad87-00d4296ca30c --><!-- end item dc7ce24f-d48a-4686-b156-b6dcd2dcf407 -->","subChapters":[]},{"id":"dc5a4084-6113-5e2c-9ac6-ca3b4c1d4a15","slug":"dabigatran","fullItemName":"Dabigatran","depth":3,"htmlHeader":"<!-- begin field c1d23808-ce8e-4de9-bb33-45bcf4dda0d5 --><h3>What are the licensed indications for dabigatran?</h3><!-- end field c1d23808-ce8e-4de9-bb33-45bcf4dda0d5 -->","summary":null,"htmlStringContent":"<!-- begin item d81301ed-3483-4bb0-b134-1814389e6f27 --><!-- begin field 5c91ec3b-e925-4ee1-a571-cfea91427bdf --><ul><li><strong><strong>Dabigatran is licensed for [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020b</a>]</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>]:</strong><ul><li>Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more of the following risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2012b</a>]:<ul><li>Previous stroke or transient ischemic attack.</li><li>Age 75 years and older.</li><li>Hypertension.</li><li>Diabetes mellitus.</li><li>Symptomatic heart failure (New York Heart Association [NYHA] Class 2 or higher).</li></ul></li><li>Prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or total knee replacement surgery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2008</a>].</li><li>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2014a</a>].</li><li>Prevention of recurrent DVT and PE in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2014a</a>].</li></ul></li></ul><!-- end field 5c91ec3b-e925-4ee1-a571-cfea91427bdf --><!-- end item d81301ed-3483-4bb0-b134-1814389e6f27 -->","subChapters":[]},{"id":"71d1ed2d-c6fd-531c-8dd9-8d177d9ad3fa","slug":"edoxaban","fullItemName":"Edoxaban","depth":3,"htmlHeader":"<!-- begin field d17a49d0-89f8-4011-9acf-0fa097b8a3d0 --><h3>What are the licensed indications for edoxaban?</h3><!-- end field d17a49d0-89f8-4011-9acf-0fa097b8a3d0 -->","summary":null,"htmlStringContent":"<!-- begin item 61b02274-d6d4-4ce2-a147-229a4e6ae03d --><!-- begin field 87e977ea-474c-4cdf-8abc-55afeae389be --><ul><li><strong>Edoxaban is licensed for [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>] </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>]</strong><strong>: </strong><ul><li>Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more of the following risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2015b</a>]:<ul><li>Previous stroke or transient ischaemic attack.</li><li>Age greater than 75 years.</li><li>Hypertension. </li><li>Diabetes mellitus. </li><li>Congestive heart failure.</li></ul></li><li>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2015c</a>].</li><li>Prevention of recurrent DVT and PE in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2015c</a>].</li></ul></li></ul><!-- end field 87e977ea-474c-4cdf-8abc-55afeae389be --><!-- end item 61b02274-d6d4-4ce2-a147-229a4e6ae03d -->","subChapters":[]},{"id":"97a5d401-3094-58f0-b4f8-bb33e14d7e11","slug":"rivaroxaban","fullItemName":"Rivaroxaban","depth":3,"htmlHeader":"<!-- begin field 30556c88-578b-4489-8c6a-93807b08152f --><h3>What are the licensed indications for rivaroxaban?</h3><!-- end field 30556c88-578b-4489-8c6a-93807b08152f -->","summary":null,"htmlStringContent":"<!-- begin item 94bc4cbd-aa69-47b9-b664-b7237ae7c60a --><!-- begin field a044e7ce-99ec-47f1-a8f2-9fa52e0e6c80 --><ul><li><strong>Rivaroxaban is licensed for [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>]:</strong><ul><li>Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more of the following risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2012c</a>]:<ul><li>Previous stroke or transient ischaemic attack.</li><li>Age greater than 75 years.</li><li>Hypertension.</li><li>Diabetes mellitus.</li><li>Congestive heart failure.</li></ul></li><li>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2012d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2013b</a>].</li><li>Prevention of recurrent DVT and PE in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2012d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2013b</a>].</li><li>Prevention of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2009</a>].</li><li>Prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2015d</a>].</li><li>Prevention of atherothrombotic events in people with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events (in combination with aspirin) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">NICE, 2019</a>].</li></ul></li></ul><!-- end field a044e7ce-99ec-47f1-a8f2-9fa52e0e6c80 --><!-- end item 94bc4cbd-aa69-47b9-b664-b7237ae7c60a -->","subChapters":[]},{"id":"ea69b6bd-7ee6-5ba2-842e-84e2300c9e76","slug":"warfarin","fullItemName":"Warfarin","depth":3,"htmlHeader":"<!-- begin field 70258289-82a0-4b78-9d9f-925b6a5581d1 --><h3>What are the indications for warfarin?</h3><!-- end field 70258289-82a0-4b78-9d9f-925b6a5581d1 -->","summary":null,"htmlStringContent":"<!-- begin item 2ac51918-3cc8-44c6-b756-e64b6dcbfa44 --><!-- begin field a008b825-fc56-4e36-91e9-4bbbcf52c29d --><ul><li><strong>Warfarin is licensed for </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020f</a>]</strong><strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>]</strong><strong>:</strong><ul><li>Prophylaxis of systemic embolism in people with rheumatic heart disease and atrial fibrillation.</li><li>Prophylaxis after insertion of prosthetic heart valves.</li><li>Prophylaxis and treatment of venous thrombosis and pulmonary embolism.</li><li>Transient ischaemic attacks.</li></ul></li></ul><!-- end field a008b825-fc56-4e36-91e9-4bbbcf52c29d --><!-- end item 2ac51918-3cc8-44c6-b756-e64b6dcbfa44 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}